Advances in molecular and genomic technologies are transforming oncology diagnostics, bridging screening, risk stratification, and treatment selection into a connected model of early cancer detection.
As a leading cause of death worldwide, cancer remains one of the most pressing challenges in modern healthcare.1 Improving survival outcomes depends on timely and accurate testing, access to high-quality treatment, and effective long-term follow-up care.
Among advances in cancer management over the past two decades, one of the most profound revolutions has occurred in diagnostics. While a cancer diagnosis can be life-changing for any individual, it also marks the beginning of a structured clinical journey. Once limited to identifying malignancy and confirming disease, oncology diagnostics now extends far beyond detection. It informs clinical decisions throughout the cancer pathway, from identifying individuals at risk, to guiding targeted therapy and monitoring treatment response.
This evolution marks a fundamental shift in healthcare, from reactive disease management to proactive prevention and personalised care. Reflecting this, the NHS 10 Year Plan emphasised earlier diagnosis, faster diagnostic pathways, and equitable access to innovation.2
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.